Pancreatic Cancer Research

ResearcherInnsbruck Medical UniversityActive in the last 2 years

Manuel Maglione

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1479-6129; OpenAlex author ID A5047678864. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
20
Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 4 papers

Papers 8

  1. Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5024↗
  2. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
  3. Patterns, timing and predictors of recurrence following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: an international multicentre retrospectiv… Co-author DOI 10.1016/j.hpb.2024.11.015↗
  4. Venous Resection During Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma-A Multicentre Propensity Score Matching Analysis of the Recurrence After Whi… Last author DOI 10.3390/cancers17071223↗
  5. Five-year recurrence/survival after pancreatoduodenectomy for pancreatic adenocarcinoma: does pre-existing diabetes matter? Results from the Recurrence After W… Co-author DOI 10.1016/j.hpb.2024.04.010↗
  6. Does an extensive diagnostic workup for upfront resectable pancreatic cancer result in a delay which affects survival? Results from an international multicentr… Co-author DOI 10.14701/ahbps.23-042↗
  7. Complement and Fungal Dysbiosis as Prognostic Markers and Potential Targets in PDAC Treatment. Last author DOI 10.3390/curroncol29120773↗
  8. Micro- and Mycobiota Dysbiosis in Pancreatic Ductal Adenocarcinoma Development. Last author DOI 10.3390/cancers13143431↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ruben Bellotti · 3 shared papers, 2021–2025 · strength 0.47
  2. Cornelia Speth · 2 shared papers, 2021–2022 · strength 0.30
  3. Duncan R.C. Spalding · 2 shared papers, 2023–2025 · strength 0.28
  4. Alberto Porcu · 2 shared papers, 2023–2025 · strength 0.28
  5. Thomas Brendon Russell · 2 shared papers, 2023–2025 · strength 0.28
  6. Fabio Ausania · 2 shared papers, 2023–2025 · strength 0.28
  7. Ricky Harminder Bhogal · 2 shared papers, 2023–2025 · strength 0.28
  8. Somaiah Aroori · 2 shared papers, 2023–2025 · strength 0.28
  9. Ismael Domínguez-Rosado · 2 shared papers, 2023–2025 · strength 0.28
  10. Dhanny Gomez · 2 shared papers, 2023–2025 · strength 0.28
  11. Brian Ritchie Davidson · 2 shared papers, 2023–2025 · strength 0.28
  12. Keith John Roberts · 2 shared papers, 2023–2025 · strength 0.28
  13. Peter Lawrence Zaki Labib · 2 shared papers, 2023–2025 · strength 0.28
  14. Andrew Malvern Smith · 2 shared papers, 2023–2025 · strength 0.28
  15. Zaed Z. R. Hamady · 2 shared papers, 2023–2025 · strength 0.28
  16. Daniel Gerald Croagh · 2 shared papers, 2023–2025 · strength 0.28
  17. Elizabeth Pando Rau · 2 shared papers, 2023–2025 · strength 0.28
  18. Adam Enver Frampton · 2 shared papers, 2023–2025 · strength 0.28
  19. Bilal A. Al-Sarireh · 1 shared paper, 2025 · strength 0.16
  20. Ashray Rajagopalan · 1 shared paper, 2023 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.